Duhen, Rebekka http://orcid.org/0000-0001-7426-0794
Ballesteros-Merino, Carmen
Frye, Alexandra K. http://orcid.org/0000-0001-5846-5175
Tran, Eric http://orcid.org/0000-0001-9070-0980
Rajamanickam, Venkatesh http://orcid.org/0000-0001-6864-7589
Chang, Shu-Ching
Koguchi, Yoshinobu
Bifulco, Carlo B.
Bernard, Brady
Leidner, Rom S. http://orcid.org/0000-0003-0788-7938
Curti, Brendan D.
Fox, Bernard A.
Urba, Walter J.
Bell, R. Bryan http://orcid.org/0000-0002-3775-109X
Weinberg, Andrew D. http://orcid.org/0000-0003-1617-7276
Article History
Received: 31 October 2019
Accepted: 24 January 2021
First Online: 16 February 2021
Competing interests
: A.D.W. is the founder of AgonOx, which has licensed the use of OX40 agonist patents for therapeutic use in cancer patients. The remaining authors declare no competing interests.